Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic Hepatitis C.

Tram T. Tran1, Paul Martin

  • 1Liver Transplant Program, Cedars Sinai Medical Center and University of California, Los Angles, School of Medicine, 8635 West 3rd Street, #590W, Los Angeles, CA 90048, USA. Martinpx@cshs.org

Current Treatment Options in Gastroenterology
|November 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterisation of CD4+ T-cell subtypes using single cell RNA sequencing and the impact of cell number and sequencing depth.

Scientific reports·2020
Same author

Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era.

Kidney international reports·2020
Same author

Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms.

Annals of the rheumatic diseases·2020
Same author

The Farewell Symphony.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2020
Same author

Navigating urology's new normal and mitigating the effects of a second wave of COVID-19.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2020
Same author

Lived experiences of social support in Paralympic swimmers: A protocol for a qualitative study.

BMJ open·2020
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and liver transplants. New therapies combining pegylated interferons with ribavirin show promise for sustained virologic response, considered a cure for HCV.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Hepatitis C virus (HCV) causes 40% of chronic liver disease in the US and is the primary reason for liver transplants.
  • An estimated 4 million Americans are or have been infected with HCV.
  • Current standard treatment involves recombinant interferon alfa and ribavirin.

Purpose of the Study:

  • To review the current and emerging treatments for chronic hepatitis C virus infection.
  • To discuss factors predicting treatment response and therapeutic goals.
  • To highlight patient management considerations, including counseling and monitoring.

Main Methods:

  • Review of current literature on hepatitis C virus (HCV) treatment.
  • Analysis of factors influencing sustained virologic response (SVR).

Related Experiment Videos

  • Discussion of therapeutic goals and management strategies.

    • Main Results:

    • Pegylated interferons combined with ribavirin are becoming the standard of care.
    • Sustained virologic response (SVR) is increasingly viewed as a cure for HCV.
    • Predictive factors for SVR include non-genotype 1 viral strains, low viral load, absence of cirrhosis, younger age, female gender, and shorter infection duration.

    Conclusions:

    • Treatment decisions should consider disease severity, comorbidities, and contraindications.
    • Patient counseling on transmission, natural history, and abstinence is crucial.
    • Close monitoring for side effects of interferon (depression, bone marrow suppression) and ribavirin (hemolytic anemia) is necessary.